Apyx Medical Financial Results
Apyx Medical reported Q3 2026 total revenue of $14.0 million, up 9% year-over-year, driven by 17% growth in its Surgical Aesthetics segment. The company narrowed its net loss to $1.8 million and achieved positive Adjusted EBITDA of $0.4 million while initiating the full commercial launch of its power liposuction handpiece for the AYON system.
- Term
- Q3 2026
“We are pleased to report 17% growth in our Surgical Aesthetics business for the quarter, reflecting continued adoption of AYON and the progress we are making in executing our commercial strategy. Over the past year, we have continued to demonstrate the value AYON offers by providing a full suite of complementary body contouring capabilities in one integrated platform. We are building on that foundation with the broader commercial launch of power liposuction, which has received very positive early feedback from surgeons since it received FDA clearance earlier this year. We estimate that approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON’s appeal.”
Charlie Goodwin, President and Chief Executive Officer